Lung Cancer Resource Links
Cancer resources
Below you will find the names of some organizations that offer information and support for people living with cancer and/or their care partners.
Genentech and Astellas are not affiliated with and do not endorse any of the listed organizations. The information provided by Genentech and Astellas is for informational purposes only and is not meant to replace a healthcare provider's (HCP) advice.
By selecting any of the links below, you will be leaving Tarceva.com and going to a site that is not controlled by or affiliated with Genentech, Inc. or Astellas Pharma US, Inc.
General cancer resources
American Cancer Society (ACS)
1 (800) ACS-2345
(1-800-227-2345)
CancerCare
1 (800) 813-HOPE
(1-800-813-4673)
Cancer Support Community
1 (888) 793-WELL
(1-888-793-9355)
National Cancer Institute (NCI)
1 (800) 4-CANCER
(1-800-422-6237)
National Coalition for Cancer Survivorship (NCCS)
1 (888) 650-9127
Resources to help quit smoking
National Quitline
1 (800) QUITNOW
(1-800-784-8669)
QuitNet
Lung Cancer Resources
The Bonnie J. Addario Lung Cancer Foundation (BJALCF)
1-415-357-1278
Caring Ambassadors Lung Cancer Program (CAP Lung Cancer)
1-503-632-9032
Lung Cancer Alliance (LCA)
1 (800) 298-2436
LUNGevity Foundation
1-312-464-0716
National Lung Cancer Partnership (NLCP)
1-608-233-7905
Uniting Against Lung Cancer
1-212-627-5500
Tarceva Patient Support Line
The Tarceva Patient Support Line is a free resource that lets you speak with an oncology nurse expert any time, 24 hours a day, 7 days a week. This service is provided by Genentech and Astellas. Language translators are available to help you.

Tarceva is prescribed for patients with advanced-stage Non-small Cell Lung Cancer (NSCLC) whose cancer has not spread or grown after initial treatment with certain types of chemotherapy. (Maintenance treatment)
Tarceva is prescribed for patients with advanced-stage Non-Small Cell Lung Cancer (NSCLC) whose cancer has spread or grown after receiving at least 1 chemotherapy regimen. (2nd/3rd-line treatment)
Tarceva is not meant to be used at the same time as certain types of chemotherapy for NSCLC.
There have been reports of serious adverse events involving the lungs in a small number of patients taking Tarceva. These events have included death in some patients. The medical name for these types of events is interstitial (in-tur-STISH-ul) lung disease-like events (or ILD-like events).
Liver and/or kidney problems (including deaths) have been reported in some patients taking Tarceva. Let your healthcare provider (HCP) know if you have a history of liver or kidney disease.
Some patients taking Tarceva have developed a hole in the lining of their stomach or intestines (including deaths). It may happen more in patients who are taking certain other medicines or who have had certain stomach or intestinal diseases.
Some patients taking Tarceva have developed serious skin conditions. Some patients have died from these conditions.
Some patients taking Tarceva have developed eye irritation and damage to the cornea. The cornea is the clear part of the eyeball that covers the colored part of the eye and the pupil. Other eye problems such as abnormal eyelash growth, dry eyes, or changes in eyesight have also been reported. Patients should tell their HCP about eye problems that get worse, including eye pain.
Women should not become pregnant while on treatment with Tarceva. If you are already pregnant or become pregnant while taking Tarceva, you should talk with your HCP about the benefits and risks of continuing to take Tarceva. DO NOT breast-feed while receiving treatment with Tarceva.
Call your HCP right away if you have these signs or symptoms:
- New or worsening skin rash
- Serious or ongoing diarrhea, nausea, loss of appetite, or vomiting
- New or worsening shortness of breath or cough
- Eye irritation
Some patients taking Tarceva have experienced difficulty with blood clotting, and bleeding events, including gastrointestinal and non-gastrointestinal bleeding. Patients taking blood thinners (Coumadin®, warfarin or other coumarin-derivatives) should be monitored regularly.
Certain medicines and herbal supplements can affect how Tarceva works in the body. It is important that you tell your HCP about all of the medicines and herbal supplements you are taking. DO NOT start taking any new medicines or herbal supplements before talking with your HCP. Tarceva may also affect other medications you are taking.
In addition, grapefruit and grapefruit juice have an effect on how Tarceva works. DO NOT eat grapefruit or drink grapefruit juice while on treatment with Tarceva, except under the care of your HCP.
Smoking may affect how well Tarceva works for you. If you smoke, you should stop smoking before starting treatment with Tarceva. Talk with your HCP about how to quit smoking. If you continue to smoke, you should talk to your HCP before taking Tarceva.
The most common side effects in patients who took Tarceva were generally mild to moderate rash and diarrhea. You may also have other changes in your skin.
The rash from Tarceva therapy may appear on your upper body or face. Typically rash occurs within 8 days of starting treatment, but it may occur any time during treatment with Tarceva.
The rash is not an allergic reaction. It may look like acne or dry skin. It is not acne. Talk to your HCP if a rash occurs.
Typically, diarrhea may develop within 12 days of starting Tarceva.
Hair and nail changes have been seen with Tarceva.
Always let your HCP know if you have any side effects, and ask about the best way to handle them.
Tarceva is not right for everyone. Ask your HCP if once-daily Tarceva is right for you.


